Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials
Endocrinology, Diabetes & Metabolism · 2025-03 · 8 (2)
DOI: 10.1002/edm2.70039 ↗At a glance
Metaanalyse in Endocrinology, Diabetes & Metabolism, published online on 2025-03-14. Written by Jawad Basit and 9 co-authors. Institution: Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan. Major MEDLINE topics: Hyperlipidemias, RNA, Small Interfering. Cited 10 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Inclisiran, a small interfering RNA (siRNA), reduces the levels of low‐density lipoproteins (LDL) in the body by preventing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). However, there is limited pooled data regarding the efficacy and safety of inclisiran in patients with hypercholesterolemia.
Methods
PubMed/MEDLINE, Embase and the Cochrane Library were searched by investigators from inception till July 2024 to identify randomised controlled trials (RCTs) that investigated inclisiran in patients with hypercholesterolemia. Weighted mean differences (MDs) for continuous outcomes and risk ratios (RRs) for the dichotomous outcomes were pooled. The analysis was conducted using the random effects model, and a p ‐value of < 0.05 was considered statistically significant.
Results
A total of 8 RCTs reporting data for 5016 patients were included in the pooled analysis. Our pooled analysis demonstrated that inclisiran was associated with a significant decline in the % of LDL‐C levels (MD = −50.42, 95% CI: −56.15 to −44.70), % of PCSK9 levels (MD = −78.57, 95% CI: −81.64 to −75.50), % of total cholesterol levels in the body (MD = −31.22, 95% CI: −33.08.15 to −29.37), and apo B levels (MD = −41.47, 95% CI: −44.83 to −38.11) when compared with the control group. The risk of all‐cause death, cardiovascular death, major adverse cardiovascular events, myocardial infarction, stroke, and serious adverse events remained comparable ( p > 0.05) across the two groups.
Conclusion
Inclisiran reduces LDL‐C, PCSK9, cholesterol and apo‐B levels in the body without increasing the risk of serious adverse events.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
- Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, India.
- Department of Medicine, Foundation University Medical College, Islamabad, Pakistan.
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Nursing Department Hamad Medical Corporation Doha, Doha, Qatar.
- Department of Medicine, King Edward Medical University, Lahore, Pakistan.
ORCID profiles: Mushood Ahmed, Priyansha Singh, Javed Iqbal, Mohammad Hamza
Cite
APA
Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025). Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism, 8(2). https://doi.org/10.1002/edm2.70039
Vancouver
Basit J, Ahmed M, Singh P, Ahsan A, Zulfiqar E, Iqbal J, et al. Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2025;8(2). doi:10.1002/edm2.70039
BibTeX
@article{Basit2025,
author = {Basit, Jawad and Ahmed, Mushood and Singh, Priyansha and Ahsan, Areeba and Zulfiqar, Eeshal and Iqbal, Javed and Fatima, Maurish and Upreti, Prakash and Hamza, Mohammad and Alraies, M Chadi},
title = {Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
volume = {8},
number = {2},
doi = {10.1002/edm2.70039}
}
EUVIMED